ifosfamide

The patient received the first cycle of the chemotherapy regimen of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide (VAC/IE) and was discharged in a stable condition. This case emphasizes the need to consider EES in the differential diagnosis of nasal masses and highlights the necessity of molecular testing for EWSR1 rearrangements to confirm the diagnosis and guide therapy. Increased awareness and reporting are vital to enhancing diagnosis and management of this rare entity.

Second-line treatment with tislelizumab, nab-paclitaxel, carboplatin, and anlotinib led to temporary stabilization. Salvage chemotherapy with doxorubicin, ifosfamide, and dacarbazine failed, and the patient died two months later...Patients who undergo complete resection of metastatic lesions tend to achieve better outcomes, whereas responses to systemic therapy are generally poor. Early identification of high-risk features and consideration of retroperitoneal lymph node dissection may improve prognosis in selected patients.

We report the case of a 38-year-old male with unresectable intra-abdominal DSRCT treated with the VAC-IE regimen (vincristine, doxorubicin, and cyclophosphamide, alternating with ifosfamide and etoposide) as first-line therapy...As second-line therapy, he received gemcitabine and docetaxel...Alternative regimens include temozolomide plus irinotecan or gemcitabine plus doxorubicin. In patients with androgen receptor positivity, hormonal blockade with leuprolide and bicalutamide may be a therapeutic option, particularly in frail patients...DSRCT is a challenging and aggressive malignancy requiring a multidisciplinary and individualized approach. The combination of systemic therapy and local control measures remains critical for improving patient outcomes.

P2/3, N=437, Active, not recruiting, Children's Oncology Group | Recruiting --> Active, not recruiting | Initiation date: Jul 2026 --> Nov 2025

P1, N=43, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Dec 2026 --> Oct 2025

P2, N=15, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

The patient was started on multimodality VAC-IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide) chemotherapy. Comprehensive imaging, histopathology, IHC, and molecular analysis remain indispensable for diagnosis. Early recognition and a multidisciplinary treatment approach are essential to improving outcomes in this aggressive disease.

P2, N=37, Recruiting, David Bond, MD | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

Both lung lesions were surgically resected, followed by adjuvant chemotherapy with ifosfamide and doxorubicin. This case emphasizes that even histologically benign-appearing prostatic SFTs can demonstrate malignant potential. It also underscores the necessity of long-term surveillance and contributes to the literature by reporting the first known case of a metastatic SFT originating from the prostate gland.

P3, N=550, Completed, Italian Sarcoma Group | Active, not recruiting --> Completed

P1/2, N=45, Completed, University of Washington | Active, not recruiting --> Completed

The trial comprised two parts: a 3 + 3 dose-escalation CDP1 monotherapy study to determine the dose for the combination study, in which 12 patients with advanced solid tumors received CDP1 alone, and a CDP1-chemotherapy combination study, in which 20 patients with recurrent or metastatic penile cancer received CDP1 combined with the paclitaxel-ifosfamide-cisplatin regimen (TIP). Among penile cancer patients receiving the combination therapy, the objective response rate was 74%, tumor downstaging enabled surgery in seven patients (35%), and the median progression-free survival was 6.9 months. In conclusion, the combination of an anti-EGFR monoclonal antibody and chemotherapy was well tolerated and showed potential efficacy in penile cancer, supporting further investigation.